About Biotechnology Business Segments Newsroom Investors INVESTORS Newsroom Press Releases PRESS RELEASES Filter between ad hoc announcements and corporate releases All Ad hoc Corporate Date Title 27.09.2021 Evolva issued 40’000’000 shares out of authorized capital AD HOC 26.08.2021 Evolva accelerated revenue growth to 60% and expects gross profit to be positive from Q4, 2021 AD HOC 17.05.2021 Evolva secures additional funding for future growth AD HOC 21.04.2021 Evolva Q1 2021 Trading Update AD HOC 08.04.2021 Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2021 AD HOC 24.03.2021 Evolva announces new Chief Financial Officer AD HOC 16.03.2021 Evolva publishes agenda for 2021 Annual General Meeting AD HOC 02.03.2021 Evolva announces Chief Financial Officer to depart AD HOC 25.02.2021 Evolva reports Full Year Results for 2020, with significant increase in customer demand for Health Ingredients and product expansion AD HOC 20.01.2021 Evolva launches L-arabinose, a natural sugar blocker and reducing sugar AD HOC 08.12.2020 Evolva secures another CHF 12 million investment from Nice & Green AD HOC 05.11.2020 Evolva continues to deliver a resilient performance during the pandemic AD HOC 26.08.2020 Evolva delivers resilient performance in a challenging environment around the globe AD HOC 10.08.2020 Evolva receives US EPA registration for nootkatone, a next-generation protection against vector-borne diseases spread by insects AD HOC 01.07.2020 Evolva: EPA public review period for nootkatone to start in the US AD HOC 29.06.2020 Evolva signs a CHF 12 million investment with Swiss company Nice & Green to fund future growth AD HOC 15.04.2020 Evolva AGM 2020: approved all resolutions proposed by the Board of Directors AD HOC 31.03.2020 Evolva standby equity distribution agreement to end AD HOC 25.03.2020 Evolva enters a new agreement with International Flavors & Fragrances (IFF) AD HOC 25.03.2020 Evolva publishes agenda for 2020 Annual General Meeting AD HOC 18.03.2020 Evolva achieves financial performance targets and makes significant progress in building the business AD HOC 21.01.2020 Evolva announces changes to the Board of Directors and Management Team to support the delivery of strategic priorities AD HOC 27.11.2019 Evolva Board of Directors proposes Beat In-Albon as new Chairman AD HOC 21.08.2019 HY RESULTS CONFIRM FULL YEAR FINANCIAL GUIDANCE. PORTFOLIO EXPANSION TO SUPPORT FUTURE GROWTH AD HOC 30.07.2019 Evolva to publish half-year results on 21 August 2019 AD HOC 08.04.2019 Evolva shareholders approve all Board proposals at AGM AD HOC 08.04.2019 Stuart Strathdee to retire from the Board of Directors of Evolva AD HOC 18.03.2019 Evolva receives a notice from US EPA on its next-generation active ingredient against ticks and mosquitoes AD HOC 04.03.2019 Joint venture to bring EverSweet TM sweeteners to market faster is finalized AD HOC 28.02.2019 After successfully completing its transformation, Evolva is on track to build its business AD HOC 09.11.2018 Evolva business update AD HOC 08.11.2018 Evolva business update AD HOC 09.08.2018 Evolva on track to deliver on set targets AD HOC 10.07.2018 Evolva announces Oliver Walker to succeed Simon Waddington as CEO AD HOC 02.05.2018 Evolva shareholders approve all Board proposals at AGM AD HOC 20.03.2018 Cargill officially starts producing its next-generation sweetener, EverSweet AD HOC 20.03.2018 Evolva provides 2017 financial results and business highlights Cargill announces the start of commercial production of EverSweet TM AD HOC 25.01.2018 Evolva provides preliminary 2017 financial highlights and business update AD HOC 08.11.2017 Evolva announces the successful completion of the CHF 86 million rights offering and private placement AD HOC 26.10.2017 Evolva announces final terms of proposed capital increase AD HOC 26.10.2017 Evolva shareholders approve EGM proposal AD HOC 12.10.2017 Evolva announces pricing of the private placement to Pictet Asset Management and Cologny Advisors LLP AD HOC 02.10.2017 Evolva provides update on strategy and announces financing plans AD HOC 11.09.2017 Evolva awarded contract by US government to advance novel pest control product AD HOC 30.08.2017 Evolva announces major restructuring for next phase of its development AD HOC 14.08.2017 Evolva announces financial results for the first half of 2017 AD HOC 06.07.2017 Neil Goldsmith stepping down as CEO and Board member of Evolva AD HOC 12.06.2017 Scott Fabro to join Evolva as chief commercial officer AD HOC 01.06.2017 Evolva in contract negotiations with the US government for funding to advance nootkatone against Zika AD HOC 16.05.2017 Evolva shareholders approve all AGM proposals that voted on Board of Directors withdraws three proposals prior to vote AD HOC 20.04.2017 Gerard Hoetmer, formerly at Unilever and Corbion, proposed to succeed Sir Tom McKillop as Evolva Chairman AD HOC 03.04.2017 Evolva announces long-term commercial agreement with Cargill AD HOC 30.03.2017 Evolva publishes financial results for 2016 and updates on projects AD HOC 15.03.2017 Evolva secures equity financing of up to CHF 30 million and provides further preliminary financials for 2016 AD HOC 09.03.2017 Evolva achieves second milestone in fragrance & flavour alliance with Takasago AD HOC 10.01.2017 Evolva provides update on stevia collaboration and 2016 preliminary top-line numbers AD HOC 19.12.2016 Pivotal Evolva stevia sweetener patent receives US Notice of Allowance AD HOC 29.11.2016 Evolva appoints Oliver Walker as CFO AD HOC 27.10.2016 ERS Genomics and Evolva Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications AD HOC 24.10.2016 Evolva pre-launches portal for online product sales AD HOC 20.09.2016 Evolva to transition to new CFO AD HOC 18.08.2016 Evolva publishes financial results for the first half of 2016 and provides business update AD HOC 17.08.2016 Evolva enters partnership on active pharmaceutical ingredients AD HOC 15.08.2016 Potential for nootkatone to one day help fight Zika virus and Lyme disease explained in a short animated video AD HOC 10.08.2016 Evolva’s collaboration with US Navy to focus on resveratrol-based composites AD HOC 04.08.2016 Evolva establishes sales office in Singapore AD HOC 28.07.2016 Cornelius and Evolva bring new fermented resveratrol to market AD HOC 25.07.2016 Evolva’s nootkatone enters NIH-sponsored studies to assess its effectiveness against mosquitoes that transmit Zika virus AD HOC 01.06.2016 U.S. FDA issues GRAS No Objection Letter for EverSweet™ next-generation sweetener AD HOC 26.05.2016 Evolva granted pivotal patent for commercial production of best-tasting fermentation-derived steviol glycosides AD HOC 19.05.2016 Ingredient commercialisation pioneer joins Evolva AD HOC 13.05.2016 Evolva shareholders approve all Board proposals at AGM AD HOC 13.04.2016 Evolva proposes Gerard Hoetmer as new Board member AD HOC 11.04.2016 Evolva to co-develop next-generation materials with US Navy AD HOC 05.04.2016 Evolva gains exclusive license to develop and commercialise nootkatone globally for pest control AD HOC 30.03.2016 Evolva publishes financial results for 2015 and updates on projects AD HOC 24.03.2016 Evolva expanding its nootkatone research with CDC to include mosquitoes that transmit Zika and other viruses AD HOC 02.03.2016 Evolva achieves milestones in flavour & fragrance alliance with Takasago AD HOC 19.01.2016 Evolva clarifies key points in recent bank analyst note AD HOC 23.12.2015 Evolva achieves stevia milestone AD HOC 10.12.2015 Evolva supports science education program in India to reduce human-elephant conflict AD HOC 07.12.2015 Evolva launches valencene AD HOC 26.11.2015 Evolva supports research to better understand the fungi underpinning rainforest biodiversity in Malaysian Borneo AD HOC 18.11.2015 Evolva reaches second milestone in collaboration to develop next-generation, sustainably produced cosmetic ingredients with L’Oréal AD HOC 03.11.2015 Evolva sells former head office AD HOC 02.11.2015 Evolva successfully completes Roquette collaboration, triggering a fourth milestone payment AD HOC 16.09.2015 Evolva announces results of the rights offering AD HOC 07.09.2015 Evolva supports University of Toronto periodontitis research AD HOC 03.09.2015 Evolva announces details of rights offering AD HOC 26.08.2015 Evolva announces intention for capital increase to support stevia launch and other growth initiatives AD HOC 21.08.2015 Evolva launches nootkatone for F&F,US EPA letter facilitates potential approval as tick and insect repellent AD HOC 20.05.2015 Evolva CEO exercises options, increases his shareholding in Evolva AD HOC 18.05.2015 Evolva reaches third milestone in Roquette collaboration AD HOC 12.05.2015 Evolva shareholders approve all Board proposals in AGM AD HOC 11.05.2015 Cargill and Evolva Start Engineering Work on Production Facility for Next-Gen Stevia Sweeteners,Evolva informs Cargill of intent to exercise 45% option AD HOC 23.04.2015 Evolva completes transfer of EV-035 to Emergent BioSolutions, triggering a USD 4 million payment AD HOC 31.03.2015 Evolva publishes financial results for 2014 AD HOC 26.03.2015 Evolva and Valent BioSciences to co-develop agricultural bioactives AD HOC 10.03.2015 Ajinomoto project moves into the next phase triggering a milestone payment to Evolva AD HOC 09.02.2015 Evolva provides financial and project update AD HOC Head to top HOME About Biotechnology Business Segments Newsroom Investors Contact SUBSCRIBE TO OUR PRESS RELEASES SUBSCRIBE All rights reserved Imprint Legal Notice